TLSA — Tiziana Life Sciences Ltd

Nasdaq · Health Care · Pharmaceuticals · CIK 1723069 ·
Last close
$1.15
Market Cap
$146.35M
52W High
$1.58
52W Low
$0.87
ADV30
876,557
Next earnings
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 11,495,000 4,010,000 11,443,000
Dec 2024 11,284,000 3,724,000 7,348,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-163,109,000
Inventory
Receivables
$4,257,000
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -21,132,000 -18,431,000 11,495,000 11,443,000 -12,847,000
Dec 2024 0 -15,794,000 -11,863,000 11,284,000 7,348,000 -1,526,000
Dec 2023 0 -17,984,000 -17,691,000 12,184,000 6,648,000 -15,698,000
Dec 2022 0 -14,586,000 -15,397,000 26,477,000 6,906,000 -19,615,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.20

Peers — same industry

TickerNameMarket CapLastDaily %
UNCY Unicycive Therapeutics, Inc. $146.28M $5.34
CNTB Connect Biopharma Holdings Ltd $144.84M $2.30
NRXP NRX Pharmaceuticals, Inc. $149.37M $3.45
SMNR Semnur Pharmaceuticals, Inc. $142.73M $0.62
AARD Aardvark Therapeutics, Inc. $150.57M $6.88

News headlines (Yahoo Finance, 1h cache)

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
2026-08-24 12:35 · Yahoo
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
2026-08-24 11:00 · Yahoo
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
2026-08-06 11:00 · Yahoo
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
2026-07-31 12:55 · Yahoo
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
2026-07-31 11:00 · Yahoo
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
2026-07-22 11:00 · Yahoo
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
2026-06-25 13:05 · Yahoo
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
2026-06-25 11:00 · Yahoo
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
2026-05-28 11:00 · Yahoo
Wall Street ends on a mixed note as Dow gains despite semiconductor slump
2026-08-24 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.